ViiV Healthcare has increased the number of countries covered by a license agreement for dolutegravir to the Medicines Patent Pool to include all lower middle income countries.
The existing license includes coverage for low-income countries, such as sub-Saharan Africa; the extension expands the reach to Armenia, Moldova, Morocco and Ukraine. With the extension, more than 94 percent of adults in the developing world with HIV will have access to treatment. Dolutegravir is approved in the U.S. as Tivicay.
ViiV was formed in 2009 by GlaxoSmithKline and Pfizer.